---
title: "美国 FDA 批准上海复宏汉霖生物技术股份有限公司的 HLX14 产品用于八项适应症。"
description: "美国 FDA 批准上海复宏汉霖生物技术股份有限公司的 HLX14 产品用于八项适应症。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255460935.md"
published_at: "2025-09-01T11:27:41.000Z"
---

# 美国 FDA 批准上海复宏汉霖生物技术股份有限公司的 HLX14 产品用于八项适应症。

美国 FDA 批准上海复宏汉霖生物技术股份有限公司的 HLX14 产品用于八项适应症。

### Related Stocks

- [02696.HK - 复宏汉霖](https://longbridge.com/zh-CN/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Henlius Biotech Receives CSRC Approval for H Share Full Circulation | Shanghai Henlius Biotech Inc. has received approval from the China Securities Regulatory Commission (CSRC) for the full  | [Link](https://longbridge.com/zh-CN/news/272805634.md) |
| Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer | Shanghai Henlius Biotech Inc. has initiated a phase 1b/2 clinical trial for HLX43, an anti-PD-L1 antibody-drug conjugate | [Link](https://longbridge.com/zh-CN/news/275577160.md) |
| Henlius Biotech Gets US FDA Nod to Conduct Trial of Tumor Drug | Henlius Biotech Gets US FDA Nod to Conduct Trial of Tumor Drug | [Link](https://longbridge.com/zh-CN/news/270305904.md) |
| Shanghai Henlius Biotech Inc. Held Extraordinary General Meeting | Shanghai Henlius Biotech Inc. held its fourth extraordinary general meeting on December 31, 2025, where shareholders app | [Link](https://longbridge.com/zh-CN/news/271199708.md) |
| Henlius Biotech Gets US FDA Nod for Breast Cancer Drug's Biologics License Application | Henlius Biotech Gets US FDA Nod for Breast Cancer Drug's Biologics License Application | [Link](https://longbridge.com/zh-CN/news/265891382.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。